Business
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022.\n\nChris Peetz, Mirum’s president and chief executive officer, will provide an overview of Mirum’s strategy and ongoing development program, as well as a commercial update for LIVMARLI™ (maralixibat) oral solution. Mr. Peetz and members of Mirum’s leadership team will be available for one-on-one meetings during the conference.\n\nPresentation and Q&A Session\n\nDate: Tuesday, January 11, 2022\nTime: 1:30 – 2:10 p.m. ET\n\nA live audio webcast and archive of Mirum’s presentation along with accompanying slides will be available in the Investors & Media section of the company’s website.\n\nAdditionally, the company will participate in a fireside chat at the upcoming H.C. Wainwright Virtual BIOCONNECT 2022 Conference. A webcast of the presentation will be accessible from the Investors & Media section of Mirum’s website beginning January 10, 2022, at 7:00 a.m. ET.\n\nVisit the Investors and Media section of Mirum’s corporate website for additional information.\n\nAbout Mirum Pharmaceuticals, Inc.\n\nMirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI™ (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.\n\nMirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.\n\nMirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.\n\nMirum’s second ...